vimarsana.com

Latest Breaking News On - Phd patras university hospital - Page 1 : vimarsana.com

Paclitaxel Safety Questions in PAD: Will Capstone Data Close the Door?

After nearly 5 years, most at a TCT 2023 session agreed that the mystery of the paclitaxel signal has been solved.

New yorkUnited statesStanford universitySan franciscoJuan granadaElazerr edelmanWilliama graySahil parikhPeter schneiderVenitar chandraKonstantinos katsanosPresbyterian columbia university irving medical centerDrug administrationMd main line health lankenau heart instituteTechnology brighamMd stanford university medical center

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

Many hoped the trial would get everyone on the same page, but experts continue to hash out the results, push back, or double down.

New yorkUnited statesSan franciscoP alik farberAlik farberP kenneth rosenfieldMichaels conteSahil parikhKonstantinos katsanosAmerican heart associationMd boston medical centerMd university of californiaBlood instituteNational heartPresbyterian columbia university irving medical centerPhd patras university hospital

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Katsanos says his original meta-analysis is “perhaps” outdated since a mortality signal is not being seen with newer devices.

United statesSan franciscoErica secemskyKonstantinos katsanosPetera schneiderMd beth israel deaconess medical centerMd university of californiaBoston scientificPhd patras university hospitalPatras university hospitalBeth israel deaconess medical center

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

The highly selected, mostly white, male population has some physicians questioning the generalizability of the results.

New yorkUnited statesNew zealandGeoffrey barnesAlik farberMatthew menardSahil parikhKonstantinos katsanosMd university of michiganAmerican heart associationMd boston medical centerMd harvard medical schoolPresbyterian columbia university irving medical centerPhd patras university hospitalBoston medical centerNew england journal

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

Longer follow-up is needed to ensure the next-generation device is as effective and safe as the standard higher-dose DCB.

United statesKenneth rosenfieldErica secemskyKonstantinos katsanosMd beth israel deaconess medical centerDrug administrationPhd patras university hospitalMassachusetts general hospitalPatras university hospitalFunctional differencesWalking impairment questionnairePeripheral arteryConcerns persistBeth israel deaconess medical center

vimarsana © 2020. All Rights Reserved.